Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Ebola, fire threaten to derail Commonwealth Youth Games
1 Sep 2015 at 8:37pm
By Greg Stutchbury AUCKLAND (Reuters) - The Commonwealth Games Federation's desire to develop competition for younger athletes survived one blow but suffered another within minutes at the organization's general assembly on Wednesday. The organization had barely stared down a request for sanctions be leveled against Samoa, just days before the 2015 Commonwealth Youth Games began, before Caribbean nation St Lucia withdrew from hosting the 2017 Games for financial reasons. Samoa, which is hosting the fifth edition of the Youth Games from Sept. 5-11, had refused to issue visas to the Sierra Leone team due to the fear of the Ebola virus in west Africa.
Games-Ebola, fire threaten to derail Commonwealth Youth Games
1 Sep 2015 at 8:35pm
By Greg Stutchbury AUCKLAND, Sept 2 (Reuters) - The Commonwealth Games Federation's desire to develop competition for younger athletes survived one blow but suffered another within minutes at the organisation's general assembly on Wednesday. The organisation had barely stared down a request for sanctions be levelled against Samoa, just days before the 2015 Commonwealth Youth Games began, before Caribbean nation St Lucia withdrew from hosting the 2017 Games for financial reasons. Samoa, which is hosting the fifth edition of the Youth Games from Sept. 5-11, had refused to issue visas to the Sierra Leone team due to the fear of the Ebola virus in west Africa.
Missouri executes man who raped, killed teenage girl
1 Sep 2015 at 8:06pm
Missouri on Tuesday executed a man who, along with a friend, pleaded guilty to the 1989 abduction, rape and murder of a 15-year-old girl, a state corrections department spokesman said. Roderick Nunley, 50, was pronounced dead at 9:09 p.m. CDT after receiving a lethal injection of drugs at the state's death chamber in Bonne Terre, Missouri, corrections spokesman Mike O'Connell said. Nunley pleaded guilty to the murder of Ann Harrison, a Kansas City high school girl who was waiting for her school bus on a March morning when he and accomplice Michael Taylor drove by and decided to kidnap and rape her, according to court papers.
Soccer-Liberia back home for Nations Cup qualifiers
1 Sep 2015 at 5:41pm
Liberia will host their first full international match since the lifting of an Ebola ban when they play Tunisia in an African Nations Cup qualifier in Monrovia on Saturday. Liberia last hosted an international in May 2014 when they beat Lesotho 1-0 in a Nations Cup qualifier in the capital. The suspension was lifted this May when the World Health Organisation (WHO) declared the country fee of the deadly haemorrhagic fever.
How Successful Product Managers Avoid Burnout
1 Sep 2015 at 5:38pm
I recently spoke with multiple former PMs who needed to take year-long sabbaticals to get themselves back on track. They were tired. Their anxiety was running high. They could not seem to get any of their goals accomplished. They were in a funk. Sound familiar?Every product manager goes through this each day. Some find their way out...
Number of California inmates observed for Legionnaires' disease jumps
1 Sep 2015 at 4:55pm
The number of inmates being observed for possible infection with Legionnaires' disease at San Quentin State Prison near San Francisco has jumped from 71 to 85, but the number of confirmed diagnoses held steady at six, authorities said Tuesday. Prison authorities said they have begun restoring some freedom of movement, as well as access to the law library and hot meals to inmates at the California prison who were put on lockdown to avoid infection when the outbreak began last week. For that reason, prison officials initially shut down the plumbing in the prison, which houses 3,700 inmates and has 1,800 employees.
Two Royals players sidelined with chicken pox
1 Sep 2015 at 4:38pm
(Reuters) - The Kansas City Royals have been almost unstoppable this season but on Tuesday they faced a very different challenge with two of their players sidelined by chicken pox. Outfielder Alex Rios and reliever Kelvin Herrera have both succumbed to the highly contagious disease and are expected to be out for up to two weeks after being sent home and placed in quarantine, the team said. Manager Ned Yost told reporters before Tuesday's game against the Detroit Tigers that the rest of the clubhouse appeared to be fit.
Baseball-Two Royals players sidelined with chicken pox
1 Sep 2015 at 4:24pm
The Kansas City Royals have been almost unstoppable this season but on Tuesday they faced a very different challenge with two of their players sidelined by chicken pox. Outfielder Alex Rios and reliever Kelvin Herrera have both succumbed to the highly contagious disease and are expected to be out for up to two weeks after being sent home and placed in quarantine, the team said. Manager Ned Yost told reporters before Tuesday's game against the Detroit Tigers that the rest of the clubhouse appeared to be fit.
FDA issues warning letters to powdered caffeine distributors
1 Sep 2015 at 4:17pm
COLUMBUS, Ohio (AP) ? The Food and Drug Administration has issued warning letters to five distributors of pure powdered caffeine, saying the products put consumers at risk.
Who Do You Trust?
1 Sep 2015 at 4:12pm
"I can't believe he lied to me!"Recently, even in the PrEP (Pre-Exposure Prophylaxis) Facts Forum, a participant remarked that one of his tricks lied to him about being on PrEP. "How can this happen?," he pondered -- it does all the time.Two years ago on the online site Manhunt, I was contacted by an HIV- guy even though my profile said "HIV+...
California assisted suicide bill advances in special session
1 Sep 2015 at 4:07pm
By Sharon Bernstein SACRAMENTO, Calif. (Reuters) - A controversial bill to allow physician-assisted suicide for terminally ill patients in California passed a key legislative committee on Tuesday, after failing in the legislature earlier this summer amid opposition from the Catholic Church. The bill was pulled from consideration in the legislature's regular session in July but was reintroduced last month as part of a special session on healthcare called by Democratic Governor Jerry Brown. "The more time we've had to work on it, the more support we have," said Senator Bill Monning, a Democrat from Carmel who is a co-author of the bill.
Medical specialists urge more debate on gene-editing technology
1 Sep 2015 at 4:04pm
By Kate Kelland LONDON (Reuters) - Medical researchers called on Wednesday for detailed, thoughtful debate on future use of new genetic technology that has the potential to create "designer babies". The technology, called CRISPR-Cas9, allows scientists to edit virtually any gene they target, including in human embryos, enabling them to find and change or replace genetic defects. Describing CRISPR as "game-changing", the Wellcome Trust global medical charity and four other leading British research organizations urged the scientific community to proceed considerately, allowing time and space for ethical debate.
Mayor of Oregon town arrested on possession of methamphetamine
1 Sep 2015 at 3:55pm
The 68-year-old mayor of a tiny town in Oregon has been charged with possession of methamphetamine, police said on Tuesday. Cletus Moore was arrested early on Monday morning during a traffic stop in Jefferson, Oregon, Marion County Sheriff's Office spokesman Chris Baldridge said. Moore is mayor of Idanha, a town of less than 140 people east of the state capital of Salem.
CNN tweaks Republican debate rules in a way that may let Fiorina in
1 Sep 2015 at 3:54pm
By Steve Holland WASHINGTON (Reuters) - CNN changed its rules on Tuesday for the next Republican presidential debate in a way that could give former business executive Carly Fiorina a chance to take the stage with the main contenders for the party's 2016 presidential nomination. The cable network, which is sponsoring the Sept. 16 debate, said any candidate who ranks in the top 10 in polling since the first debate on Aug. 6 would be included in the next prime-time debate. CNN originally had planned to include polling data dating to July 16 to determine the participants, but Fiorina criticized that plan because it would not have taken into account her surge in support since the first debate.
Missouri to execute killer of Kansas City high school girl
1 Sep 2015 at 3:41pm
Roderick Nunley, 50, is scheduled to be put to death by lethal injection at 6 p.m. (7 p.m. EDT) in the state's death chamber in Bonne Terre, Missouri. Nunley pleaded guilty to the murder of Ann Harrison, a Kansas City high school girl who was waiting for her school bus on a March morning when he and accomplice Michael Taylor drove by and decided to kidnap and rape her. After assaulting her, the two men stabbed Harrison multiple times and left her body in the trunk of a car they had stolen.